Zhao Rong Sheng

TDM

TDM:(010)82265810:[email protected] (2006) (1998) (1991) 1998.08, 、 、 、 、 、 、, 、 1991.08-1995.07, 1.,: irAEs “FOCUS-ML”,2025-2028,40,; 2.,:,2021-2024,48,; 3.,“ ”:,2021-2025,200,; 4.,:《 》,2024-2025,4,; 5. 2023,:,2023-2025,40,; 6.,:,2023-2025,50,; 7., ( - ):,2022-2025,67.5,; 8., ( - ):,2023-2025,1500,; 9.: 、 、 、 、 、 I,2025,319.1,; 10.,:,2021-2022,30,.,ACCP,; 、;;;;;;;;;;; American Journal of Health-System Pharmacy; 《 》; 《 》; 《 》、《 》. (2024 ) 1. Zaiwei Song#, Dan Jiang#, Lingling Yu, Yixuan Chen, Daobin Zhou, Yue Li, Depei Wu, Lingli Zhang, Liyan Miao, Jun Ma*, Jun Zhu*, Hongmei Jing*, Rongsheng Zhao*. Evidence-based expert consensus on clinical management of safety of Bruton's tyrosine kinase inhibitors (2024). Chinese journal of cancer research, 36(3), 240–256. doi: 10.21147/j.issn.1000-9604.2024.03.02 (Q1, IF=7, T1 ) 2. Zhe Zhao#, Jing Chen, Danhua Zhao, Baoyu Chen, Qi Wang, Yuan Li, Junyi Chen, Chaobo Bai, Xintong Guo, Nan Hu, Bingwei Zhang, Rongsheng Zhao* & Junliang Yuan*. (2024). Microbial biomarker discovery in Parkinson's disease through a network-based approach. NPJ Parkinson's disease, 10(1), 203. doi: 10.1038/s41531-024-00802-2 (Q1, IF=6.7) 3. Xin Xiong#, Xunke Gu, Xiaona Li, Keke Jia, Yuan Wei*, Rongsheng Zhao*. (2024). A chemical derivatization-based pseudotargeted liquid chromatography-tandem mass spectrometry method for sensitive and high coverage determination of bile acids in human serum. Analytica chimica acta, 1287, 342119. doi: 10.1016/j.aca.2023.342119 (Q1, IF=5.7) 4. Xiaona Li#, Zhini Liu#, Zhuo Li, Xin Xiong, Xianhua Zhang, Changqing Yang*, Libo Zhao*, Rongsheng Zhao*. (2024). A simple, rapid and sensitive HILIC LC-MS/MS method for simultaneous determination of 16 purine metabolites in plasma and urine. Talanta, 267, 125171. doi: 10.1016/j.talanta.2023.125171 (Q1, IF=5.6) 5. Ping Yang#, Wei Liu#, Yingqiu Ying#, Libo Zhao#, Xin Xiong, Xianhua Zhang, Yinchu Cheng, Congya Zhou, Yuanyuan Zhang, Xiaona Li, Jiamin Xu, Li Yang*, Rongsheng Zhao*. (2024). Population pharmacokinetics of nirmatrelvir in Chinese patients with COVID-19: Therapeutic drug monitoring and dosing regimen selection in clinical practice. International journal of antimicrobial agents, 64(2), 107199. doi: 10.1016/j.ijantimicag.2024.107199 (Q1, IF=4.9) 6. Xinya Li#, Zaiwei Song#, Yixuan Chen, Jingjing Wu, Dan Jiang, Zhen Zhang, Zeyuan Wang* & Rongsheng Zhao*. (2024). Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal. Cancer immunology, immunotherapy, 74(1), 2. doi: 10.1007/s00262-024-03816-0 (Q1, IF=4.6) 7. Yi Ma#, Zaiwei Song#, Xinya Li, Dan Jiang, Rongsheng Zhao* & Zhanmiao Yi*. (2024). Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy. Clinical pharmacokinetics, 63(3), 279–291. doi: 10.1007/s40262-024-01358-3 (Q1, IF=4.6) 8. Shujie Dong#, Yalan Wang#, Jialu Bian, Hongsheng Chen, Jie Dong, Jun Zhu, Tongyan Zhang, Qian Du* & Rongsheng Zhao*. (2024). The effect of omega-3 Polyunsaturated Fatty Acid (PUFA) prescription preparations on the prevention of clinical cardiovascular disease: a meta-analysis of RCTs. Nutrition journal, 23(1), 157. doi: 10.1186/s12937-024-01051-y (Q1, IF=4.4) 9. Xinya Li#, Zaiwei Song#, Zhanmiao Yi#, Jiguang Qin, Dan Jiang, Zhitong Wang, Huibo Li, Rongsheng Zhao*. (2024). Therapeutic drug monitoring guidelines in oncology: what do we know and how to move forward? Insights from a systematic review. Therapeutic advances in medical oncology, 16, 17588359241250130. doi: 10.1177/17588359241250130 (Q2, IF=4.3) 10. Dan Jiang#, Zaiwei Song#, Yi Ma#, Xu Zhang, Hao Bing, Xin Xiong, Yang Hu, Fei Dong* & Rongsheng Zhao*. (2024). Development, validation, and clinical application of LC-MS/MS method for simultaneous determination of ibrutinib, zanubrutinib, orelabrutinib, acalabrutinib, and their active metabolites in patients with B-cell lymphoma. Analytical and bioanalytical chemistry, 417(4), 821–834. doi: 10.1007/s00216-024-05701-2 (Q1, IF=3.8) 11. Hongsheng Chen#, Shuang Liu, Lingling Yu, Xiaofei Hou, Rongsheng Zhao*. (2024). Factors and interventions affecting tacrolimus intrapatient variability: A systematic review and meta-analysis. Transplantation reviews, 38(4), 100878. doi: 10.1016/j.trre.2024.100878 (Q1, IF=3.6) 12. Yang Hu#, Zaiwei Song#, Yuan Gao#, Dan Jiang, Yiwen Ran, Yi Ma, Huibo Li, Rongsheng Zhao*. (2024). Is therapeutic drug monitoring a dancing partner for TNF-α inhibitors in real-world practice? Answers from an updated systematic review and meta-analysis. Expert review of clinical pharmacology, 1–14. doi: 10.1080/17512433.2024.2403641 (Q2, IF=3.6) 13. Yanjing Shi#, Shujie Dong#, Yang Xu, Dongze Ji, Li Yang, Rongsheng Zhao*. (2024). Acute kidney injury events in patients with diabetes using sodium glucose transporter 2 inhibitors: a meta-analysis of cohort studies. Acta diabetologica, 61(6), 755–764. doi: 10.1007/s00592-024-02252-x (Q2, IF=3.1) 14. Yi Ma#, Chang Wei#, Zixi Yi, Zaiwei Song, Yinchu Cheng, Lin Zeng, Rongsheng Zhao*, Rong Mu*. (2024). Do rheumatic diseases, long-term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID-19 severity? Insight from a retrospective cohort study. International journal of rheumatic diseases, 27(7), e15251. doi: 10.1111/1756-185X.15251 (Q2, IF=2.4) 15. #, #,,,,,,, *. (2024)[J]., 2024,35(16):1933-1945. 16. #, *,,. " - " [J]., 2024,33(6):401-407. 1.,,《 》“ ”《 》; 2.,,《 》; 3.,,《 》(“ ” ); 4.,,《 》; 5.,,《 》; 6.,,《 》(“ ” ); 7.,,《 》 - • “ ” 2021 / STAR 3 “ ”“ ” 3 ESI